The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
Status:
Recruiting
Trial end date:
2021-12-27
Target enrollment:
Participant gender:
Summary
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase
II/III trial, and will be conducted globally. The study is comprised of two parts: dose
selection (Phase II) and pivotal treatment effect (Phase III).